Structured Formula (Formula)
Fluticasone Propionate
Product Images NDC 50090-3803
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate (NDC 50090-3803). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Table1 (Table1)
This is a table titled "Drug-Related Adverse Events — Skin" that presents the results of a study of the drug Fluticasone. The study compared the effects of using Fluticasone once daily versus using it twice daily, as well as comparing Fluticasone treatment to a vehicle control group. The table lists various skin reactions and the frequency of their occurrence as observed in the study participants, broken down by treatment group.*
Table2 (Table2)
This is a table presenting the adverse events reported in a pediatric open-label trial of Fluticasone administered twice daily. The table includes the number and percentage of patients who experienced each specific adverse event, such as burning or urticaria. The text advises readers to refer to the full text for further information.*
Table3 (Table3)
This is a table displaying the physician's assessment of clinical response for Fluticasone Propionate Cream and its vehicle in two different studies. The table indicates the percentage of participants in each study who were evaluated as cleared, excellent, good, fair, poor, or worse. The results show varying levels of effectiveness in the different studies.*
Table4 (Table4)
This is a table showing mean improvements of clinical signs over baseline in a study involving Fluticasone Propionate Cream and a vehicle. The clinical signs measured include erythema, thickening, and scaling. Additionally, the table shows four different studies identified as Study 1, Study 2, Study 3, and Study 4.*
Table5 (Table5)
The given text is a table displaying the clinical response assessment made by a physician for two studies conducted using Fluticasone Propionate Cream, once and twice daily respectively. The assessments are categorized as Cleared, Excellent, Good, Fair, Poor, and Worse. The table shows the percentage distribution of each category of clinical response in four subgroups of study participants.*
Table6 (Table6)
This is a tabular presentation of the clinical signs and symptoms mean improvements over baseline in two studies conducted on Fluticasone Propionate cream. The table compares the effectiveness of the cream used once daily and twice daily in reducing the signs of skin irritation such as erythema, pruritus, thickening, lichenification, vesiculation, and crusting.*
Label Image (Lbl500903803)
The text is not available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
